Veranova Appoints Thomas Rohrer VP of Bioconjugation

Veranova, a global developer and manufacturer of specialty and complex active pharmaceutical ingredients (APIs) for the pharma and biopharma sectors, has appointed Thomas Rohrer as Vice President of Bioconjugation. This appointment follows a recently announced investment to establish cGMP bioconjugation capabilities at its Devens, MA site.

Thomas brings more than 40 years of experience and a comprehensive understanding of biological process development and clinical manufacturing, including 30 years of licensed biological manufacturing. Throughout his career, he has successfully delivered complex biological programs for both clinical and commercial applications, including mammalian, microbial, vaccine, and gene therapy drug substances.

He spent 16 years at Lonza, where he led teams across several locations and departments, including Biopharmaceutical Manufacturing, Antibody Drug Conjugation, Biochemical Technologies, Project Evaluation and Commercial Development. His industry experience also includes Director of Process Development at Human Genome Sciences (later acquired by GSK), Otsuka America Pharmaceutical, Guidepoint Global LLC, Gentz Biopharmaceutical Consulting LLC, and most recently as Senior Director of Bioconjugate Technology Support at Samsung Biologics.

“We are delighted to welcome Tom as our Vice President of Bioconjugation,” said Rohtash Kumar, Senior Vice President of Development Operations and Chief Technology Officer at Veranova. “His invaluable experience and thought leadership in biological manufacturing will be critical as we continue to build and grow our bioconjugation offering in Devens, providing a more comprehensive suite of services to partners developing Antibody Drug Conjugates and other bioconjugates.”